Biovitrum terminates preclinical program in obesity
All rights are returned by GlaxoSmithKline
During the early phase of the program Biovitrum completed clinical phase II trials with the 5-HT-agonist BVT.993. It was found that BVT.933 significantly reduced body weight in patients without causing any serious side effects. However, the compound was not considered to be sufficiently selective and in 2003 the project was brought back for further preclinical studies. Since then the work has been focused on finding other compounds even more selective for the 5-HT2c receptor. GSK now returns all rights to the project to Biovitrum, which, subsequently, has decided not to develop the compounds further for the obesity indication. However, the compounds will be evaluated for other indications.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.